Outcome of allogeneic hematopoietic stem-cell transplantation in 50 patients with acutemyeloid leukemia and MLL rearrangement
10.3760/cma.j.cn421203-20201007-00350
- VernacularTitle:伴MLL基因重排的急性髓性白血病allo-HSCT治疗50例疗效分析
- Author:
Xinhong FEI
1
;
Shuqin ZHANG
;
Fan YANG
;
Weijie ZHANG
;
Haoyu CHENG
;
Yuming YIN
;
Jingbo WANG
Author Information
1. 航天中心医院血液科，北京 100049
- Keywords:
Hematopoietic stem cell transplantation;
Mixed lineage leukemia;
Gene rearrangement
- From:
Chinese Journal of Organ Transplantation
2021;42(8):464-467
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia associated with 11q23/MLL.Methods:Retrospection and analysis 50 cases of acute myeloid leukemia with 11q23/MLL and who were treated with allogeneic hematopoietic stem cell transplantation(allo-HSCT)in our hospital from September 2012 to December 2019. The efficacy was evaluated by analyzing the transplantation success rate, graft-versus-host disease rate, infection rate, transplant-related mortality(TRM), accumulative recurrence rate, disease-free survival rate(DFS), and overall survival rate(OS).Results:Except for 1 patient had an unsuccessful stem cell transplantationas the result of multiple organ failure, the remaining 49 patients were successfully transplanted. The median time of leukocyte transplantation was 15(9~18)days, and the median time of platelet transplantation was 13(8~33)days. Bone marrow was assessed 28 days after transplantation, and 49 patients were in CR status. The median follow-up time was 38(3~79)months. Between remission group and non-remission group after transplantation, the 3-year OS rates were(83.3±10.8)%, (30.9+ 8.2)%( P=0.002)and the 3-year DFS rates were(83.3+ 10.8)%, (28.4±8.0)%( P=0.003), respectively. Conclusions:Allogeneic hematopoietic stem cell transplantation is an effective method for the treatment of 11q23/MLL rearranged AML. Patients in remission before transplantation have a higher survival rate, and recurrence after transplantation is the primary problem currently faced.
